Cytosorbents (CTSO) Common Equity (2010 - 2026)

Cytosorbents' Common Equity history runs 17 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• Quarterly Common Equity fell 84.91% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 84.91% YoY) and the FY2025 annual result came in at $5.9 million, down 46.85% from the prior year.
• Common Equity was $2.2 million for Q1 2026 at Cytosorbents, down from $5.9 million in the prior quarter.
• Across five years, Common Equity topped out at $55.4 million in Q1 2022 and bottomed at $2.2 million in Q1 2026.
• A 5-year average of $22.3 million and a median of $18.8 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2025 — Common Equity slipped 25.89% — and 2026, when it plunged 84.91%.
• Cytosorbents' Common Equity stood at $35.4 million in 2022, then plunged by 33.63% to $23.5 million in 2023, then slumped by 52.7% to $11.1 million in 2024, then slumped by 46.85% to $5.9 million in 2025, then sank by 62.83% to $2.2 million in 2026.
• Business Quant data shows CTSO's Common Equity at $2.2 million in Q1 2026, $5.9 million in Q4 2025, and $9.0 million in Q3 2025.